In recent clinical cases, TRAUMAGEL has shown effectiveness during tourniquet conversion in prolonged field care scenarios. The cases involved various types of injuries such as gunshot wounds, industrial trauma, and sharp-force injuries. Cresilon Inc., a biotechnology company based in Brooklyn, reported on July 7, 2026, the successful application of TRAUMAGEL in these instances. The promising results were seen in a range of cases, highlighting the product's potential in emergency medical situations. Overall, the use of TRAUMAGEL demonstrated positive outcomes in managing injuries during tourniquet conversions, shedding light on its value in critical care protocols.